NCT06251986Completed
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice: the CRONOS-MS Study.
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
This was a non-interventional, cross-sectional, multicentric, and nationwide study, based on primary and secondary data collection.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 310 (actual)
- First submitted
- 1 Feb 2024
- Start date
- 26 Feb 2024
- Primary completion date
- 23 Dec 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT06251986
What you commit to
- Study type: Observational
- Participants enrolled: 310
- From 26 Feb 2024 to the primary completion date, 23 Dec 2024
- 25 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Currently participating in a clinical trial.
- Not able/unlikely to complete with all study activities according to investigator's criteria.
- Have a contraindication for ofatumumab use, according to the SmPC.
Who the study is looking for
- Aged ≥ 18 years.
- Written informed consent.
- Diagnosis of RMS per McDonald Criteria (2017).
- Ofatumumab treatment in line with the European Kesimpta® summary of product characteristics (SmPC; i.e. adult patients with RMS with active disease defined by clinical or imaging features) during at least 12 months and patients who discontinued ofatumumab after receiving at least one dose with a minimum monitoring of 12 months.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (25)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.